Viking Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Viking Therapeutics, Inc. carries a market capitalization of 3.87B, placing it among publicly traded companies globally. Its enterprise value stands at 4.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.87B |
| Enterprise Value | 4.05B |
Share Statistics
Viking Therapeutics, Inc. currently has 116.65M shares outstanding.
| Shares Outstanding | 116.65M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 11.14 |
| P/TBV Ratio | 11.14 |
| P/FCF Ratio | -10.68 |
| P/OCF Ratio | -10.68 |
Financial Position
Viking Therapeutics, Inc. maintains a current ratio of 4.72, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.72 |
| Quick Ratio | 4.57 |
| Debt / Equity | 1.00 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -88.85 |
| Return on Assets (ROA) | -79.24 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Viking Therapeutics, Inc.'s stock has declined approximately -17.08718% over the past 52 weeks. The 50-day moving average sits at 34.55, while the 200-day moving average is 33.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -17.08718% |
| 50-Day Moving Average | 34.55 |
| 200-Day Moving Average | 33.78 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -559.57M, while operating income came in at -560.02M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -560.02M |
| Pretax Income | -534.80M |
| Net Income | -534.80M |
| EBITDA | -559.57M |
| EBIT | -560.02M |
| Earnings Per Share (EPS) | -4.67 |
Balance Sheet
Viking Therapeutics, Inc. holds 501.66M in cash and equivalents against 4.09M in total debt, resulting in a net debt position of -125.75M. Total book value stands at 408.32M, with working capital of 407.91M providing operational flexibility.
| Cash & Cash Equivalents | 501.66M |
| Total Debt | 4.09M |
| Net Debt | -125.75M |
| Equity (Book Value) | 408.32M |
| Book Value Per Share | 3.50 |
| Working Capital | 407.91M |
Cash Flow
Viking Therapeutics, Inc. produced -418.44M in operating cash flow over the past twelve months.
| Operating Cash Flow | -418.44M |
| Capital Expenditures | N/A |
| Free Cash Flow | -418.44M |
| FCF Per Share | -3.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.44 |
| FCF Yield | -9.36 |
Scores
Viking Therapeutics, Inc. posts an Altman Z-Score of 18.39, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 18.39 |